Oaklander welcomed the news of the approval of the new vaccine, saying that more adults should be vaccinated against shingles. In the United States alone, there are an estimated 1 million cases of shingles a year, and one in three people can expected to develop the condition during their lifetime.
6 brokerages have issued twelve-month price objectives for Arbutus Biopharma Corp's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Arbutus Biopharma Corp's stock price to reach $7.00 in the next year.
In this case, BioPharmX Corporation finds support just below today's level at $0.14. If this is broken, then the next support from accumulated volume will be at $0.13 and $0.12. The stock is about to test the resistance from accumulated volume at $0.16 and this may cause the stock to take a minor break or get into a more sideways move for a few days.